Two-drug combination for relapsed Waldenstrom macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs—mosunetuzumab and pirtobrutinib—in patients whose Waldenstrom macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The study aims to see if this combination can shrink tumors and help patients feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with confirmed Waldenstrom macroglobulinemia diagnosis
- Your disease has come back or no longer responds to prior treatment, and you've received at least one previous therapy
- You must have either tried a BTK inhibitor drug before or actively chosen not to take one
- Adequate blood cell counts and organ function (kidneys, liver, heart)
- No prior stem-cell transplant from a donor, though your own stem-cell transplant is okay if done 100+ days ago
- Able to swallow pills and comply with study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs, zanubrutinib and BGB-11417, for people with Waldenström Macroglobulinemia who have already had at least one prior treatment. The goal is to see if this two-drug approach works better than standard options.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This Phase 2 trial studies zanubrutinib combined with BR (bendamustine and rituximab) in adults newly diagnosed with Waldenström macroglobulinemia (WM) who have symptoms. It may help shrink the abnormal disease and improve symptoms like high blood stickiness, nerve problems, anemia, and other lymphoma-related issues.
This trial tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) for people with Waldenstrom's macroglobulinemia (a rare blood cancer) who have not yet had treatment. It aims to see if the combination is safe and effective.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.